{"id":"W2590983141","doi":"10.1182/blood.v118.21.811.811","title":"Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Bortezomib; Internal medicine; Multiple myeloma; Clinical endpoint; Panobinostat; Oncology; Progression-free survival; Phases of clinical research; Clinical trial; Surrogate endpoint; Gastroenterology; Adverse effect; Chemotherapy; Histone deacetylase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004986001,0.0002407308,0.0008347767,0.0002160798,0.0000288558,0.000008227598,0.0001028324,0.0001053706,0.00002187653],"category_scores_gemma":[0.0007131969,0.0001590532,0.00008171134,0.0004381122,0.0001598186,0.0001723282,0.00003348485,0.0002128336,0.000006094621],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001059214,"about_ca_system_score_gemma":0.0002158855,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001296895,"about_ca_topic_score_gemma":0.0008516806,"domain_scores_codex":[0.9976814,0.0002661537,0.0006638948,0.0003935885,0.0006084329,0.0003865499],"domain_scores_gemma":[0.9986858,0.0002573007,0.000289486,0.0003932696,0.0001905971,0.0001834924],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5851503,0.02010353,0.3926503,0.0000362221,0.0001968155,0.0002509805,0.0003206504,2.533772e-7,0.00002060919,0.0000170291,0.000008679596,0.001244609],"study_design_scores_gemma":[0.6401595,0.007035785,0.3514935,0.0001687111,0.0001409225,0.000003003138,0.00004181402,0.00004310792,0.0007891927,0.00001623671,0.000008152352,0.0001000672],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939412,0.00005920338,0.00002052052,0.0000187985,0.00005061174,0.004221087,0.0001758736,0.00002857085,0.00148413],"genre_scores_gemma":[0.9980201,0.00002543709,0.001335453,0.00001089733,0.00001761131,0.0001966003,0.0003250274,0.00002332347,0.00004558068],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0550092,"threshold_uncertainty_score":0.6486002,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01980632799239791,"score_gpt":0.2789102579825956,"score_spread":0.2591039299901977,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}